A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
This phase I trial studies the side effects and best dose of trametinib in treating patients
with cancer that has spread to other places in the body and usually cannot be cured or
controlled with treatment (advanced) with or without liver (hepatic) dysfunction. Trametinib
may stop the growth of tumour cells by blocking proteins needed for cell growth. When these
proteins are blocked, the growth of cancer cells may be stopped and the cancer cells will
then die. Hepatic dysfunction is frequently found in patients with advanced cancer and
usually prevents patients from receiving standard treatments or from participating in
clinical trials. Patients may also need dose adjustments or absorb drugs differently.
Trametinib may be a better treatment for patients with advanced cancers and hepatic
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society